发明申请
- 专利标题： MODIFIED iRNA AGENTS
- 专利标题（中）： 改性iRNA代理
-
申请号： US13822441申请日： 2011-09-14
-
公开(公告)号： US20130317080A1公开(公告)日： 2013-11-28
- 发明人: Kallanthottathil G. Rajeev , Tracy Zimmermann , Muthiah Manoharan , Martin Maier , Kevin Fitzgerald
- 申请人： Kallanthottathil G. Rajeev , Tracy Zimmermann , Muthiah Manoharan , Martin Maier , Kevin Fitzgerald
- 申请人地址： US MA Cambridge
- 专利权人： ALNYLAM PHARMACEUTICALS, INC.
- 当前专利权人： ALNYLAM PHARMACEUTICALS, INC.
- 当前专利权人地址： US MA Cambridge
- 国际申请： PCT/US11/51597 WO 20110914
- 主分类号： C12N15/113
- IPC分类号： C12N15/113
摘要：
The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.
公开/授权文献
- US09290760B2 Modified iRNA agents 公开/授权日：2016-03-22
信息查询
IPC分类:
